Baseline characteristics of fallers versus non-fallers in a remote, decentralized study of Parkinson’s disease
Objective: To compare the baseline characteristics of fallers versus non-fallers in a remote, decentralized study of Parkinson’s disease (PD) participants. Background: Falls are common in…Axonal-demyelinating polyneuropathy after subcutaneous foslevodopa/foscarbidopa infusion – case report.
Objective: The aim of this report was to present a patient with Parkinson’s disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) who developed axonal-demyelinating…Two-year Outcomes of Restless Legs Syndrome Following Globus Pallidus Interna Deep Brain Stimulation for Parkinson’s Disease
Objective: This study evaluated two-year outcomes of Restless Legs Syndrome (RLS) in a cohort of patients with Parkinson’s disease (PD) who underwent deep brain stimulation…Aggregation – Dependent Effects of Wild-Type and Mutant α-Synuclein on Synaptic Membrane Fusion
Objective: 1. What is the endogenous form of ⍺-Synuclein in various cell types?2. How do WT ⍺-Synuclein monomer and aggregates affect presynaptic membrane fusion and the…Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide
Objective: To review the safety data of opicapone (OPC) after 10 years of worldwide marketing experience. Background: OPC, a third-generation COMT inhibitor, is approved as…Peripheral neuropathy (NP) in advanced Parkinson’s disease (PD) patients treated with continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD)
Objective: To assess peripheral NP occurrence and clinico-electrophysiological features in patients with advanced PD patients treated with continuous subcutaneous fLD/fCD. Background: Continuous subcutaneous fLD/fCD is effective…Exposure-Response Analysis of Glovadalen in the ATLANTIS Phase II Study: Trial Simulation Explains Dose-Response for OFF Time in Parkinson’s
Objective: This analysis characterized the exposure-response (E-R) relationship of glovadalen (UCB0022) in the ATLANTIS Phase-IIa proof-of-concept study, to understand the apparent lack of dose-response for…Astrocyte Derived Extracellular Vesicle miR 210 Expression in Exenatide Treated Patients with Parkinson’s Disease
Objective: To investigate miR‑210 expression in astrocyte‑derived extracellular vesicles (ADEVs) from individuals with PD treated with Exenatide versus placebo. Background: Hypoxic stress profoundly alters neuronal…MobilityAPP: A randomized-controlled trial evaluating gait-focused physiotherapy in Parkinson’s disease and atypical parkinsonian syndromes
Objective: Effect on gait and balance of gait-focused physiotherapy compared to standard-of-care physiotherapy in patients with MSA, PSP and PD. Background: Physiotherapy is a crucial element…Automated Speech Analysis for the Differentiation of Multiple System Atrophy from Parkinson’s Disease in an English-Speaking Cohort
Objective: The aim of this pilot study was to determine whether automatically extracted speech features, derived from targeted speech tasks, can differentiate Multiple System Atrophy…
- « Previous Page
- 1
- …
- 159
- 160
- 161
- 162
- 163
- …
- 208
- Next Page »